Internal Medicine, Endocrinology, Diabetes, & Metabolism · El Paso, TX
NPI
1437164803
Since 2006
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
1
Medicare group memberships
Hospitals
4
Hospital affiliations
1516 Lomaland Dr.
El Paso, TX, 79935
Phone (915) 593-2600
Groups this clinician bills Medicare through
Medicare paid, 2024
$83K
1,143 services
Medicare patients, 2024
422
Average age 73
Drug cost, 2024
$9.6M
15,532 prescriptions
Company payments, 2025
$102K
From 35 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Sergio F Rovner was code 99214 (office e&m - established), 685 times for 344 patients. In total Sergio F Rovner billed 1,143 services in 19 codes, and Medicare paid $83K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2016-05-02.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 685 | 344 | $73.88 | $51K |
| 99215 Office E&M - Established | Office | 217 | 120 | $103.11 | $22K |
| 99213 Office E&M - Established | Office | 74 | 59 | $43.66 | $3,231 |
| 99212 Office E&M - Established | Office | 29 | 22 | $19.60 | $569 |
| 99204 Office E&M - New | Office | 21 | 21 | $105.82 | $2,222 |
| 96372 Injection Administration | Office | 19 | 11 | $8.81 | $167 |
| 95251 Test - Miscellaneous | Office | 17 | 17 | $24.03 | $409 |
| 60100 Other Organ Systems | Office | 15 | 12 | $59.83 | $897 |
| 83036 Blood Count | Office | 15 | 15 | $8.94 | $134 |
| 76942 Ultrasound - Nonspecific | Office | 12 | 12 | $38.99 | $468 |
By year: 2022 $113K for 1,581 services; 2023 $92K for 1,280 services; 2024 $83K for 1,143 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 83036 Blood Count | 15 | 15 | $8.94 | $134 |
Medicare prescription drug claims, 2024
In 2024, the drug Sergio F Rovner prescribed most often to Medicare patients was Levothyroxine Sodium, with 1,635 prescriptions and refills. In total Sergio F Rovner wrote 15,532 Medicare prescriptions that cost $9.6M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Levothyroxine Sodium Generic | 1,635 | 4,241 | 527 | $16K |
| Ozempic Semaglutide | 1,076 | 1,602 | 271 | $1.5M |
| Mounjaro Tirzepatide | 826 | 1,086 | 190 | $1.2M |
| Atorvastatin Calcium Generic | 736 | 1,962 | 284 | $5,252 |
| Synjardy Xr Empagliflozin/Metformin Hcl | 486 | 885 | 142 | $525K |
| Rosuvastatin Calcium Generic | 443 | 1,041 | 156 | $5,136 |
| Metformin Hcl Generic | 422 | 1,062 | 167 | $5,653 |
| Jardiance Empagliflozin | 344 | 666 | 130 | $389K |
| Dexamethasone Generic | 327 | 336 | 211 | $375 |
| Lisinopril Generic | 322 | 890 | 125 | $2,343 |
| Xigduo Xr Dapaglifloz Propaned/Metformin | 312 | 578 | 92 | $307K |
| Trulicity Dulaglutide | 306 | 562 | 106 | $558K |
| Vascepa Icosapent Ethyl | 299 | 674 | 115 | $230K |
| Losartan Potassium Generic | 257 | 643 | 106 | $2,049 |
| Alendronate Sodium Generic | 251 | 674 | 103 | $1,970 |
Brand drugs: 7,337 claims; generic drugs: 7,734 claims; opioid claims: 15.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Sergio F Rovner $102K ($102K in general payments such as food, travel and fees) from 35 companies. The largest payer was Lilly USA, LLC with $31K.
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC LLY | 55 | $31K |
| Corcept Therapeutics CORT | 46 | $28K |
| Novo Nordisk Inc NVO | 23 | $16K |
| Dexcom, Inc. DXCM | 24 | $10K |
| Amgen Inc. AMGN | 30 | $6,301 |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 35 | $5,842 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 17 | $2,583 |
| Novartis Pharmaceuticals Corporation NVS | 11 | $363 |
| Recordati_rare_diseases_inc. | 10 | $326 |
| Abbott Laboratories ABT | 14 | $274 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.